Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Authors / Ayman Chit

Ayman Chit

Though my career I have always followed my passion and backed it up with as much rigor and discipline as I could. This is all paying off now nicely as I feel intellectually challenged and satisfied doing my bit to propel public health forward.” Ayman Chit is currently head of Health Economics, Modeling and Market Access at Sanofi Pasteur in North America. He started off with an undergraduate degree in chemistry and then moved on to study under the Master of Biotechnology program, both at the University of Toronto. Ayman says, “This Master was run jointly between the Business school and the Faculty of Science and it help me discover that my real calling was in economics. I then quickly moved on to completing a PhD in Health Economics, specializing in the economics of pharmaceutical development and valuation.

  • Contributions

Calculate – Don’t Estimate – Drug Development Costs

December 1, 2014

Researchers estimate the cost of drug development at over $1 billion, while others say it’s less than $100 million. Who’s right? And how can we accurately determine the true costs?

0 min read

Calculate – Don’t Estimate – Drug Development Costs

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.